Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06978660 · ClinicalTrials.gov registry record

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

A clinical trial of Transthyretin Cardiac Amyloidosis, sponsored by Idoven 1903 S.L..

Recruiting
Registry status
2,000
Enrollment target
10
Study locations

NCT06978660 is a study of Transthyretin Cardiac Amyloidosis that is actively recruiting participants, run by Idoven 1903 S.L.. The registered enrollment target is 2,000 participants, above the 136-participant average among 4 other Transthyretin Cardiac Amyloidosis trials with a reported enrollment target (1371% higher). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06978660, a study of Transthyretin Cardiac Amyloidosis, is actively recruiting participants, sponsored by Idoven 1903 S.L..

RECRUITING
Registry status
2,000 participants
Enrollment target
10
Study locations

Study Summary

CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.

Conditions Studied

Transthyretin Cardiac Amyloidosis

Study Locations (10)

Other

  • Centre Hospitalier Universitaire de Toulouse - Toulouse
  • Universitätsklinikum Bonn - Bonn
  • L'Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi - Bologna
  • Careggi University Hospital - Florence
  • United Hospitals of Trieste University Hospital - Trieste
  • Queen Elizabeth University Hospital, Univeisity of Glasgow - Glasgow

Illinois

  • Northwestern University - Evanston

Balearic Islands

  • Hospital Universitario Son Llàtzer - Palma de Mallorca

Guipúzcoa

  • Hospital Universitario Donostia - San Sebastián

Huelva

  • Hospital Universitario Juan Ramón Jiménez - Huelva

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2025-05-27
Est. Completion 2026-05

Sponsor

Idoven 1903 S.L.

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06978660

The ClinicalTrials.gov registry entry for NCT06978660 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 136-participant average among 4 other Transthyretin Cardiac Amyloidosis trials with a reported enrollment target (1371% higher). The listed sponsor is Idoven 1903 S.L., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Transthyretin Cardiac Amyloidosis appearing as the primary indexed condition, and to 0 interventions.

NCT06978660 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Other, Illinois, Balearic Islands.

Frequently Asked Questions

What is clinical trial NCT06978660 about?

NCT06978660 is a clinical study titled "Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis". CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ abil...

What is the current status of trial NCT06978660?

This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2025-05-27. Estimated completion is 2026-05.

What conditions does trial NCT06978660 study?

This clinical trial studies the following conditions: Transthyretin Cardiac Amyloidosis.

Who is sponsoring clinical trial NCT06978660?

This trial is sponsored by Idoven 1903 S.L., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06978660 being conducted?

This trial has 10 study locations across Illinois, Balearic Islands, Guipúzcoa, Huelva. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Transthyretin Cardiac Amyloidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Transthyretin Cardiac Amyloidosis

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.